# Kardigan

> Kardigan is a South San Francisco heart health company modernizing cardiovascular drug development. Founded by the team behind MyoKardia, it pairs a late-stage clinical pipeline in dilated cardiomyopathy, acute severe hypertension and calcific aortic valve stenosis with a 'cardiac intelligence' platform - real-world patient data and AI - to match disease drivers to the right responders.

- **Founded:** 2024
- **Headquarters:** South San Francisco, California, United States
- **Founders:** Tassos Gianakakos (Co-Founder, CEO and Chair), Jay Edelberg, M.D., Ph.D. (Co-Founder and Chief Medical Officer), Bob McDowell, Ph.D. (Co-Founder and Scientific Adviser), Leslie Leinwand, Ph.D. (Co-Founder), Beth McNally, M.D., Ph.D. (Co-Founder)
- **Team size:** ~120
- **Products:** Cardiac Intelligence Platform, Dilated Cardiomyopathy (DCM) Program, Acute Severe Hypertension (ASH) Program, Calcific Aortic Valve Stenosis (CAVS) Program
- **Notable:** Closed $254M Series B in October 2025, bringing total funding to ~$554M., Launched publicly in January 2025 with $300M Series A., Acquired Prolaio in March 2025 to combine therapeutics with a real-world cardiovascular data platform.

## Products & services

- **Cardiac Intelligence Platform** — Integrated cardiovascular data and analytics platform (built on the acquired Prolaio technology) that combines real-world patient data, FDA-cleared software and AI to identify disease drivers and predict patient response.
- **Dilated Cardiomyopathy (DCM) Program** — Late-stage clinical program targeting genetically defined subtypes of DCM.
- **Acute Severe Hypertension (ASH) Program** — Late-stage clinical program addressing acute severe hypertension, an area with no approved disease-modifying treatments.
- **Calcific Aortic Valve Stenosis (CAVS) Program** — Late-stage clinical program targeting the molecular drivers of CAVS.

## Achievements

- Closed $254M Series B in October 2025, bringing total funding to ~$554M.
- Launched publicly in January 2025 with $300M Series A.
- Acquired Prolaio in March 2025 to combine therapeutics with a real-world cardiovascular data platform.
- Advanced three late-stage clinical programs in indications with no approved disease-modifying treatments.

## Latest updates

- **2025-10** — Closed $254M Series B led by Fidelity and T. Rowe Price.
- **2025-03** — Acquired Prolaio, an FDA-cleared cardiovascular data platform.
- **2025-01** — Public launch with $300M Series A and reveal of three-program pipeline.

## Links

- Website: https://www.kardigan.bio
- LinkedIn: https://www.linkedin.com/company/kardigan-inc

---

Profile page: https://yespress.io/kardigan
Published by YesPress — https://yespress.io
Last updated: 2026-05-19